126 related articles for article (PubMed ID: 17803446)
1. Analysis of multiple factors related to hematologic toxicity following 153Sm-EDTMP therapy.
Liu H; Zhan H; Sun D; Xu W; Ye X; Zhang H; Zhao C; Bao C; He G; Yin F
Cancer Biother Radiopharm; 2007 Aug; 22(4):515-20. PubMed ID: 17803446
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
3. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.
Ricci S; Boni G; Pastina I; Genovesi D; Cianci C; Chiacchio S; Orlandini C; Grosso M; Alsharif A; Chioni A; Di Donato S; Francesca F; Selli C; Rubello D; Mariani G
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1023-30. PubMed ID: 17242920
[TBL] [Abstract][Full Text] [Related]
5. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
6. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
7. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
8. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.
Loeb DM; Garrett-Mayer E; Hobbs RF; Prideaux AR; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2009 Jun; 115(11):2514-22. PubMed ID: 19338063
[TBL] [Abstract][Full Text] [Related]
10. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
12. An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results.
Kendler D; Donnemiller E; Oberladstätter M; Erler H; Gabriel M; Riccabona G
Nucl Med Commun; 2004 Apr; 25(4):367-73. PubMed ID: 15097811
[TBL] [Abstract][Full Text] [Related]
13. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
14. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
15. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
Shi B; Fu Z; Lei XH
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
[TBL] [Abstract][Full Text] [Related]
17. Induction of micronuclei by 153Sm-EDTMP in peripheral blood lymphocytes of patients with bone metastases.
Suzuki MF; Silva MA; Murakami D; Guimaraes MI; Okazaki K
Cell Mol Biol (Noisy-le-grand); 2002 Jul; 48(5):487-92. PubMed ID: 12146701
[TBL] [Abstract][Full Text] [Related]
18. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
19. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
20. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone.
Alberts AS; Smit BJ; Louw WK; van Rensburg AJ; van Beek A; Kritzinger V; Nel JS
Radiother Oncol; 1997 May; 43(2):175-9. PubMed ID: 9192964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]